kpuh6bsc

Property	Value
?:abstract	The novel coronavirus pneumonia (COVID-19) is a highly infectious acute respiratory disease caused by Severe Acute Respiratory Syndrome-Related Coronavirus (SARS-CoV-2) (Prec Clin Med 2020;3:9-13, Lancet 2020;395:497-506, N. Engl J Med 2020a;382:1199-207, Nature 2020;579:270-3). SARS-CoV-2 surveillance is essential to controlling widespread transmission. However, there are several challenges associated with the diagnostic of the COVID-19 during the current outbreak (Liu and Li (2019), Nature 2020;579:265-9, N. Engl J Med 2020;382:727-33). Firstly, the high number of cases overwhelms diagnostic test capacity and proposes the need for a rapid solution for sample processing (Science 2018;360:444-8). Secondly, SARS-CoV-2 is closely related to other important coronavirus species and subspecies, so detection assays can give false-positive results if they are not efficiently specific to SARS-CoV-2. Thirdly, patients with suspected SARS-CoV-2 infection sometimes have a different respiratory viral infection or co-infections with SARS-CoV-2 and other respiratory viruses (MedRxiv 2020a;1-18). Confirmation of the COVID-19 is performed mainly by virus isolation followed by RT-PCR and sequencing (N. Engl J Med 2020;382:727-33, MedRxiv 2020a, Turkish J Biol 2020;44:192-202). The emergence and outbreak of the novel coronavirus highlighted the urgent need for new therapeutic technologies that are fast, precise, stable, easy to manufacture, and target-specific for surveillance and treatment. Molecular biology tools that include gene-editing approaches such as CRISPR-Cas12/13-based SHERLOCK, DETECTR, CARVER and PAC-MAN, antisense oligonucleotides, antisense peptide nucleic acids, ribozymes, aptamers, and RNAi silencing approaches produced with cutting-edge scientific advances compared to conventional diagnostic or treatment methods could be vital in COVID-19 and other future outbreaks. Thus, in this review, we will discuss potent the molecular biology approaches that can revolutionize diagnostic of viral infections and therapies to fight COVID-19 in a highly specific, stable, and efficient way.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/kpuh6bsc_hasAnnotation_C0597404> <https://research.tib.eu/covid-19/entity/kpuh6bsc_hasAnnotation_C0599013> <https://research.tib.eu/covid-19/entity/kpuh6bsc_hasAnnotation_C0600500> <https://research.tib.eu/covid-19/entity/kpuh6bsc_hasAnnotation_C0858952> <https://research.tib.eu/covid-19/entity/kpuh6bsc_hasAnnotation_C1175743> <https://research.tib.eu/covid-19/entity/kpuh6bsc_hasAnnotation_C1414400> <https://research.tib.eu/covid-19/entity/kpuh6bsc_hasAnnotation_C1419866> <https://research.tib.eu/covid-19/entity/kpuh6bsc_hasAnnotation_C1823219> <https://research.tib.eu/covid-19/entity/kpuh6bsc_hasAnnotation_C3658200> <https://research.tib.eu/covid-19/entity/kpuh6bsc_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/Berber%2C_Burak%3B_Aydin%2C_Cihan%3B_Kocabas%2C_Fatih%3B_Guney-Esken%2C_Gulen%3B_Yilancioglu%2C_Kaan%3B_Karadag-Alpaslan%2C_Medine%3B_Caliseki%2C_Mehmet%3B_Yuce%2C_Melek%3B_Demir%2C_Sevda%3B_Tastan%2C_Cihan>
?:journal	Gene_ther
?:license	unk
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/kpuh6bsc_HAS_C1175743_CAUSES_C0264219>
?:source	WHO
?:title	Gene editing and RNAi approaches for COVID-19 diagnostics and therapeutics
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:who_covidence_id	#977265
?:year	2020

Property

Value

?:abstract

The novel coronavirus pneumonia (COVID-19) is a highly infectious acute respiratory disease caused by Severe Acute Respiratory Syndrome-Related Coronavirus (SARS-CoV-2) (Prec Clin Med 2020;3:9-13, Lancet 2020;395:497-506, N. Engl J Med 2020a;382:1199-207, Nature 2020;579:270-3). SARS-CoV-2 surveillance is essential to controlling widespread transmission. However, there are several challenges associated with the diagnostic of the COVID-19 during the current outbreak (Liu and Li (2019), Nature 2020;579:265-9, N. Engl J Med 2020;382:727-33). Firstly, the high number of cases overwhelms diagnostic test capacity and proposes the need for a rapid solution for sample processing (Science 2018;360:444-8). Secondly, SARS-CoV-2 is closely related to other important coronavirus species and subspecies, so detection assays can give false-positive results if they are not efficiently specific to SARS-CoV-2. Thirdly, patients with suspected SARS-CoV-2 infection sometimes have a different respiratory viral infection or co-infections with SARS-CoV-2 and other respiratory viruses (MedRxiv 2020a;1-18). Confirmation of the COVID-19 is performed mainly by virus isolation followed by RT-PCR and sequencing (N. Engl J Med 2020;382:727-33, MedRxiv 2020a, Turkish J Biol 2020;44:192-202). The emergence and outbreak of the novel coronavirus highlighted the urgent need for new therapeutic technologies that are fast, precise, stable, easy to manufacture, and target-specific for surveillance and treatment. Molecular biology tools that include gene-editing approaches such as CRISPR-Cas12/13-based SHERLOCK, DETECTR, CARVER and PAC-MAN, antisense oligonucleotides, antisense peptide nucleic acids, ribozymes, aptamers, and RNAi silencing approaches produced with cutting-edge scientific advances compared to conventional diagnostic or treatment methods could be vital in COVID-19 and other future outbreaks. Thus, in this review, we will discuss potent the molecular biology approaches that can revolutionize diagnostic of viral infections and therapies to fight COVID-19 in a highly specific, stable, and efficient way.

is ?:annotates of